Traumatic brain injury (TBI) is followed by massive production of reactive oxygen species (ROS), which mediate secondary cellular damage. Low molecular weight antioxidants (LMWA) constitute one of the defense mechanisms of the brain, and their levels correlate with post-TBI outcome. Melatonin, the main pineal hormone, possesses antioxidant properties. We investigated the effects of melatonin on neurobehavioral recovery, brain LMWA, and activation of the redoxsensitive transcription factors nuclear factor-kappaB (NF-κB) and AP-1 in mice subjected to closed head injury (CHI). Given 1 h after CHI, melatonin facilitated recovery during at least 1 wk (P<0.05) and decreased lesion size by ~ twofold (P<0.01). The dose response displayed a bell-shape, i.e., neuroprotection was achieved with 5 but not 1 or 10 mg/kg. At the neuroprotective dose, melatonin treatment was associated with sustained (4 days) elevation of brain LMWA, including ascorbic acid (P<0.05). In contrast, LMWA were unaffected by the administration of the neuroprotective endocannabinoid 2-arachidonoyl glycerol. Furthermore, melatonin did not alter early phase (24 h) CHI-induced activation of NF-κB and AP-1; however, it blocked the robust late-phase (8 days) activation of NF-κB and decreased that of AP-1 to below basal levels. Our results demonstrate that melatonin induces neuroprotection, presumably via potentiation of brain antioxidants and attenuation of NF-κB and AP-1 activation.
wide spectrum of cellular responses, including the choice between cell death and survival (18) . AP-1, a heterodimeric protein consisting of c-Fos and a Jun (c-Jun, JunB, JunD) subunit, is involved in the control of cell proliferation and differentiation (19) . After TBI, AP-1 DNA binding increases in the cortex within hours (20) . NF-κB is composed of hetero-or homodimers of proteins such as p50 and p65 that under resting conditions reside in the cytoplasm as an inactive complex bound by inhibitor proteins, IκBα and IκBβ. Upon activation, IκB is phosphorylated, ubiquitinated, and degraded by the proteasome; simultaneously, the active dimer translocates to the nucleus where it initiates gene transcription (16, 18) . TBI induces early phase neuronal activation of NF-κB, followed by its remarkably prolonged activation (up to 1 yr) in glial cells (21) .
Brain antioxidant defense mechanisms include enzymes (superoxide dismutase, catalase, glutathione peroxidase, and reductase), chelating agents, and LMWA, which act as direct radical scavengers and chain-breaking antioxidants (12, 22) . The latter group is extremely important in combating oxidative stress and is comprised of several hundred compounds originating in both exogenous and endogenous sources. Kohen et al. (22) have applied the technique of cyclic voltammetry (CV) to evaluate water-and lipid-soluble antioxidants in various biological samples. Instead of measuring specific antioxidants, this approach determines the overall reducing capacity of a tissue, which correlates with the levels of its LMWA and their respective oxidation potentials.
Melatonin (N-acetyl-5-methoxytryptamine), the main product of the pineal gland, was shown to exert neuroprotection in models of brain and spinal cord trauma (23, 24) , cerebral ischemia (25) , and excitotoxicity (26) . Because acute oxidative stress is commonly involved in the progression of secondary neuronal tissue injury in these models, the neuroprotective effects of melatonin have been attributed by some authors to its activity as an antioxidant (23) (24) 26) . Indeed, numerous earlier in vitro studies provided evidence that melatonin acts as a direct scavenger of several reactive oxygen and nitrogen species (27) (28) (29) (30) . However, later studies failed to confirm the activity of melatonin as a potent direct chain-breaking antioxidant and suggested that in some circumstances it can function as a weak preventive antioxidant, presumably by acting as a weak metal ion chelator (31) (32) (33) . In light of this controversy, the present study was designed to assess the activity of melatonin as neuroprotectant in an animal model of CHI. After confirmation of neuroprotection, we investigated the effects of melatonin on post-CHI cellular antioxidant profile and redox-dependent signaling in an attempt to understand its mode of action as a neuroprotective agent.
MATERIALS AND METHODS

Animals and maintenance
Male Sabra mice (Hebrew University strain), weighing 30-42 g, were used in this study. The animals were maintained according to the regulations of the Animal Care Committee of the Hebrew University, under a 12 h light/dark reversed light cycle and food and water were provided ad libitum.
Trauma model
CHI was induced while the animals were under ether anesthesia as described previously (34) . Briefly, after a sagittal scalp incision, mice were immobilized under a cylindrical calibrated weight drop device. A tipped Teflon cone was placed 3 mm lateral to the midline and 1 mm caudal to the left coronal suture, and a metal rod (94 g) was dropped on the cone from a height of 11-14 cm (adjusted to body weight). Sham mice were treated similarly except that trauma was not induced. Experiments were conducted between 10 AM to 1 PM
Neurobehavioral evaluation and experimental groups
One hour after CHI, the clinical status of the mice was evaluated by a score of 10 tasks testing behavioral and motor function (35) . One point was awarded for failing to perform a particular task (Table 1) , thus a neurological severity score (NSS) of 10 reflecting maximal impairment. Only mice with NSS > 4 at 1 h after injury (NSS1h) were included in the study. Recovery (∆NSS t ) was defined as the difference between NSS1h and NSS at any later time point (positive ∆NSS indicating improvement whereas negative values indicating deterioration). After NSS1h assessment, mice were randomly assigned to intraperitoneal (ip) administration of a vehicle (5% ethanolic saline) or melatonin (Sigma-Aldrich Chemie GmbH) at doses of 1, 5, or 10 mg/kg. NSS was again evaluated at 24 h, and based on these results, vehicle and 5 mg/kg melatonintreated groups were chosen for reevaluation at 4 and 7 days after injury. Due to its lipophilic nature, melatonin solution was prepared daily and protected from light.
Evaluation of lesion size
Mice treated with vehicle or 5 mg/kg melatonin were decapitated 24 h after CHI, brains were carefully excised, and 1 mm thick slices were prepared using a brain mold. The slices were incubated (2 h) in a 2% solution of 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich) in PBS and fixed (24 h) in 4% formaldehyde (36) . Slices were photographed using Stemi SV11 Stereoscope (Zeiss, Germany) and a digital photocamera (Coolpix E990; Nikon, Japan). Staining was analyzed by densitometry of the acquired images using Scion Image-Release Beta 4.0.2 program. Lesion was defined as reduced intensity of ipsilateral staining, and its size was calculated as a percentage of twice the size of the intact contralateral tissue.
Cyclic voltammetry analysis
Experimental groups
The effect of melatonin (5 or 10 mg/kg) on brain antioxidants was first assessed in sham mice (n=5-11/group). We then investigated the effect of melatonin (1, 5, or 10 mg/kg) given 1 h after CHI on early (24 h) post-CHI brain antioxidants (n=10/group). Based on these results, late (4 d) post-CHI antioxidant profile was studied in mice given 5 mg/kg of melatonin or 2-arachidonoyl glycerol (2-AG; n=5-8/group). 2-AG, generously given by Prof. Mechulam from the department of Medical Chemistry and Natural Products, Hebrew University, was prepared in a mixture of ethanol:chromophor:saline (1:1:18). All experiments included sham-untreated mice and CHI mice treated with the appropriate vehicle as controls.
Sample preparation
Cortical slices (90-150 mg) were taken from either proximal or contralateral to the lesion. Homogenization in 10% (w:v) PBS (pH-7.4) was followed by centrifugation at 1000 g for 10 min (4°C). After removal of 200 µl for HPLC studies, the remaining supernatant was analyzed by CV electrochemical apparatus (BAS 50W; West Lafayette, IN) as described previously (12, 22) . An electrical linear potential gradient (0-1300 mV relative to a reference electrode) was applied at a rate of 100 mV/sec across an electrode-solution interface (working electrode) to oxidize reducing species present in the sample. Each sample was repeatedly measured, until identical voltammograms were obtained. The working electrode was burnished before each measurement with a polishing kit (BAS-PK-1). Computerized analysis (BAS Windows Control Software, Version 2.3 EF-1661) obtained voltammetric waves in a peak shaped mode. The potential (Ep) at which the peak current occurs on the voltage-axis (x) was determined, and current intensity (Ia) was calculated from the y-axis. While Ep correlates with the reducing potency of compounds, Ia is proportional to the concentration of antioxidants being oxidized at a particular Ep (22) . Ia values were normalized to protein concentration, as determined by Bradford (Sigma-Aldrich).
High-pressure liquid chromatography with an electrochemical detector analysis
Brain concentration of ascorbic acid (n=4-7/group) was determined by high-pressure liquid chromatography with an electrochemical detector (HPLC-ECD). Supernatants were treated with 20% TCA for 15 min and then centrifuged at 14000 rpm for 10 min (4°C). The upper phase was diluted with 10% TCA (1:4) and vigorously mixed before injection of 20 µl into an HPLC system (Kontron; Zurich, Switzerland). The column was connected to an LC4A amperometric electrochemical detector (BAS) with glassy carbon working electrode and an Ag/AgCl reference electrode. The mobile phase consisted of 0.1 M acetic acid buffer (pH 5.2), 0.27 mM Na 2 EDTA, and 1% tetrabutylammonium hydroxide. The flow rate was 0.8 ml/min, and the chromatograms were recorded on a PC-based data acquisition and processing system (13) . External ascorbic acid (Sigma-Aldrich) was used to create a standard curve, from which sample concentrations were calculated.
DNA binding activity of NF-κB and AP-1
Mice were decapitated 1 and 8 days after CHI or sham operation. Nuclear extracts were prepared as described previously, with minor modifications (37) . The injured cortex was dissected under ice and transferred briefly into ice-cold 0.32 M sucrose. Tissues were homogenized in ice-cold 4:1 (v:w) buffer A (0.5 M sucrose; 10 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 10% glycerol; 1mM EDTA) into which 1 mM DDT, 1 mM PMSF, 10 mM PNPP, 20 mM βGP, 0.1 mM EGTA, and protease inhibitor cocktail (1:25; Roche Diagnostics; Mannheim, Germany) were added before use. After 15 min on ice, Nonidet P40 was added to a final concentration of 0.6%, and homogenates were incubated for 5 min before centrifugation at 10,000 rpm for 5 min (4°C). Supernatants containing the cytosolic extract were kept at -80°C until they were used for IκBα immunoblotting. Pellets were rewashed with 1:1 (v:v) buffer A and centrifuged at 10,000 rpm for 5 min (4°C). Supernatants were discarded and nuclear pellets were resuspended in 1:1 (v:v) icecold buffer C (20 mM HEPES, pH 7.9; 25% glycerol; 0.42 M NaCl; 0.2 mM EDTA) containing 1 mM DDT, 0.5 mM PMSF, 10 mM PPNP, 20 mM βGP, and 0.1 mM EGTA. After 30 min incubation on ice with frequent vortexing, the samples were centrifuged for 20 min at 15,000 rpm (4°C), and the supernatants were stored at -80°C until used as nuclear extracts in the electrophoretic mobility shift assay (EMSA). The consensus sequence for NF-κB was a doublestranded oligonucleotide (5′-AGT TGA GGG GAC TTT CCC AGG C-3′; 3′-TCA ACT CCC CTG AAA GGG TCC G-5′; Promega, E3291; Madison, WI) and that for AP-1 (c-Jun) was (5′-CGC TTG ATG AGT CAG CCG GAA-3′; 3′-GCG AAC TAC TCA GTC GGC CTT-5′; Promega, E3201). Both oligonucleotides contained 5′-OH blunt ends that were labeled with 32 P (Perkin Elmer Life Sciences) using T4 polynucleotide kinase (Promega, M4101) according to the instructions of the manufacturer. The binding reaction mix, containing 10 mM HEPES (pH 7.9), 60 mM KCl, 10% glycerol, 2 µg bovine serum albumin, 0.4 mM DDT, 2 µg poly(dI-dC), 10 µg nuclear protein, and 32 P-labeled NF-κB or AP-1 oligonucleotide (20,000 and 15,0000 cpm, respectively), was incubated on ice for 1 h. Specificity of the protein-DNA complexes was confirmed by incubation (30 min) of nuclear extracts with 100x excess of unlabled NF-κB or AP-1 oligonucleotide before the respective 32 P-labeled probe was added. Supershift assay for NF-κB entailed incubation (30 min) of nuclear extracts with 1 µl of anti-p65 monoclonal antibody (Santa Cruz Biotechnology, sc8008; Santa Cruz, CA) before addition of the 32 P-labeled probe. DNA-protein complexes were resolved on a 5% polyacrylamide gel made up in 1x TGE (50 mM Tris, 400 mM glycine, 2 mM EDTA) at 100 V for 100 min. The gels were vacuum-dried and exposed to Kodak X-ray films at -80°C. Quantitative data were obtained using Bio-Rad Multi-Analyst (PC Version 1.1). Levels of NF-κB and AP-1 were expressed as the relative optical densities of CHI/sham samples within a gel. Each experiment was repeated three times, and the data represent the mean of all measurements.
IκBα immunoblotting
Cytosolic extracts (50 µg protein) were applied to sodium dodecyl sulfate (SDS) 10% polyacrylamide gels, electrophoresed, and transferred to nitrocellulose membranes (Schleicher and Schuell; Dassel, Germany). Membranes were incubated with a monoclonal anti-IκBα antibody for 2 h (1:2500 dilution) followed by 30 min incubation with peroxidase-conjugated protein A (1:10,000 dilution; Amersham Biosciences) and then analyzed according to the Amersham enhanced chemiluminescense system (ECL). Anti-IκBα was generously supplied by Prof. Ben-Neria from the Lautenberg Center for General and Tumor Immunology, Hebrew University. Quantitative data were obtained using Bio-Rad Multi-Analyst, and levels of IκBα were expressed as relative optical densities of CHI/sham samples within a gel.
Statistical analysis
All values are means ± SE. Nonparametric tests (Kruskal-Wallis, followed by Dunn's post-hoc test, or Mann Whitney U test, as appropriate) were used to analyze clinical data. Performance of individual tasks was compared by Chi-square test. Lesion size was compared by 2-tailed Student's t test. Ia values, levels of ascorbic acid, and optical densities were compared by oneway analysis of variance (ANOVA), followed by Bonferroni test for comparison between selected groups (Prizm, GraphPad software; San-Diego, CA). The level of significance was P < 0.05.
RESULTS
Effect of melatonin on clinical outcome after CHI
NSS1h was 7.2 ± 0.32 in the vehicle-treated group (n=23) and 6.5 ± 0.4 (n=10), 6.9 ± 0.3 (n=23), and 6.6 ± 0.7 (n=8) in 1, 5, and 10 mg/kg melatonin-treated groups, respectively. The similar values indicate comparable severity of trauma. As shown in Fig. 1A , CHI mice treated with 5 mg/kg melatonin displayed significantly lower neurological deficits at 24 h after injury as compared with all other groups (P=0.028, ANOVA). Within this period, none of the 5 mg/kg melatonin-treated mice displayed clinical deterioration and only 21.7% showed no clinical improvement. In contrast, 21.7% of the vehicle-treated mice deteriorated and 30.4% showed no improvement (x 2 =10.03, P<0.01, dF=2). Melatonin-treated mice performed significantly better in 7 out of 10 NSS-composing tasks (P<0.05, data not shown). We next examined the effect of a single injection of melatonin (5 mg/kg) given 1 h after CHI on clinical recovery at 4 (n=13-14) and 7 days (n=9-10). Figure 1B depicts the rate of recovery throughout this period. It is apparent that at all times, ∆NSS was significantly higher in the melatonin-treated mice as compared with the vehicle-treated group (P<0.01 and P<0.05 at 4 and 7 days, respectively).
Effect of melatonin on lesion size
TTC, a marker of mitochondrial enzyme activity (36) , stained the contralateral hemisphere a rich pink/red staining. In contrast, intensity of ipsilateral staining was prominently reduced in the penumbra of the lesion, indicative of tissue ischemia. The expected size of each brain section, calculated as twice the size of the intact contralateral hemisphere, was similar in both groups. However, lesion size was twofold smaller in melatonin-as compared with vehicle-treated mice (6.17±1.04 vs. 11.08±1.01%; n=7/group; P<0.01).
Effect of melatonin on brain antioxidants
Brain voltammograms revealed anodic waves (AWs) at 383 ± 26 mV, 764 ± 21 mV, and 1145 ± 18 mV. These represent clusters of water-soluble LMWA that differ by their reducing potential under the tested conditions. In sham mice, melatonin did not affect brain electrochemical properties (i.e., Ep) or concentrations of LMWA (Ia; data not shown). It should be noted that the Ep of melatonin itself is ~700 mV (38) . Fig. 2B ) was noted in vehicle-treated mice at ~1145mV, decreasing to near-basal levels thereafter (2.57±0.1 µA/mg protein; Fig. 2D ). In contrast, 1 day after CHI, melatonin (5 mg/kg) treatment resulted in ~44% (1.44±0.2 vs. 1.01±0.09 µA/mg protein; P<0.05; Fig. 2A ) and ~89% (4.01±0.5 vs. 2.12±0.3 µA/mg protein; P<0.01; Fig. 2B ) increments of ipsilateral Ia at ~765mV and ~1145mV, respectively. Even more so, contralateral Ia at both peaks were significantly higher in the melatonin group as compared with the vehicle group (P<0.05). Melatonin at 1 mg/kg was insufficient to augment brain LMWA, and at 10 mg/kg its favorable effect was completely abolished ( Fig. 2A and B) .
Because melatonin reduced lesion size at 24 h, we further compared its effect on late (4 day) post-CHI brain antioxidants to that of 2-AG, a neuroprotective endocannabinoid that was previously shown by us to reduce tissue injury after CHI (39) . We found that melatonin, but not 2-AG, augmented ipsilateral Ia at ~765 and ~1145mV as compared with all other control groups ( Fig. 2C and D) .
Effect of melatonin on ascorbic acid
Brain concentration of ascorbic acid was comparable in sham and 4 days post-CHI mice (27.74±3.8 vs. 31.2±3.5 µM, respectively). Melatonin did not affect brain concentration of ascorbic acid in sham mice (25.6±4.2 µM). Yet, it significantly increased brain ascorbic acid 4 days after CHI (44.2 ± 6.2 µM; P<0.05).
Effect of melatonin on DNA binding activity of NF-κB and AP-1
The temporal pattern of DNA binding activity of NF-κB after CHI is depicted in Fig. 3A . Three shifted bands were identified in EMSA, and their specificity was confirmed by their significantly lower intensity in the presence of excess unlabeled NF-κB oligonucleotide (Fig. 3A, insert) . CHI induced a progressive increase in nuclear NF-κB, already at 24 h (5.6-fold), reaching a 12.7-fold increase at day 8 (n=4-5/group/time point). Treatment with 5 mg/kg melatonin 1 h after CHI did not abolish the early increase but effectively blocked the increase at 8 day, such that NF-κB activation remained as at 24 h (P<0.05). Supershift assay with anti-p65 antibody demonstrated that the uppermost band is composed of p65 subunit. At neither time points were the cytosolic levels of IκBα altered in response to CHI (170 and 123% at 24 h and 8 days, respectively) or to melatonin treatment (124 and 107%, respectively; Fig. 3B ). Figure 4 depicts the effect of melatonin on post-CHI AP-1 activation. A single predominant shifted band was identified, and its specificity was confirmed by its abolishment in the presence of excess unlabeled AP-1 oligonucleotide. CHI induced a transient (24 h), twofold activation of AP-1 that was not affected by melatonin treatment. However, 8 days post-CHI, AP-1 DNA binding returned to baseline (90%), whereas in the melatonin-treated group it dropped to 44% of the basal levels (P<0.05).
DISCUSSION
The main findings of the present study are 1) a single administration of melatonin 1 h after CHI facilitates clinical recovery during the first posttraumatic week, 2) melatonin potentiates post-CHI brain antioxidants, and 3) melatonin does not affect early phase CHI-induced activation of NF-κB and AP-1; however, it totally blocks the late-phase robust activation of NF-κB and decreases that of AP-1 to half the basal level.
The initial NSS1h reflects the severity of injury and is a reliable predictor of late outcome, as shown by histological and MRI studies (35) . In the present study, ∆NSS, which represents the extent of recovery, remained significantly higher in 5 mg/kg melatonin-treated group throughout the entire follow-up period. Melatonin mainly improved motor and coordination performances, presumably as a result of attenuated lesion size. In addition, we showed a bell-shaped doseresponse curve, i.e., neuroprotection was obtained with 5 but not with 1 or at 10 mg/kg.
Melatonin has been shown to exert neuroprotection in a variety of oxidative stress-associated neuropathologies, including brain and spinal cord trauma (23) (24) 40) , cerebral ischemia (25, 41) , neurotoxicity (26, 42) , and models of Parkinson's (43) and Alzheimer's diseases (44) . Thus, it was suggested that melatonin exerts neuroprotection via nonreceptor-mediated activities as a free radical scavenger and as an inhibitor of lipid peroxidation. However, some of the previously described activities of melatonin as a potent antioxidant have been strongly argued in recent studies (31) (32) (33) . In light of this controversy, we were prompt to assess whether the neuroprotective effect of melatonin in our CHI model involved redox-dependent mechanisms. With the use of CV, the present study shows that melatonin induces dose-related changes in brain antioxidant profile after CHI. Because melatonin readily crosses the blood-brain-barrier (BBB; ref 45 ) and brain antioxidants were not altered after its administration to sham mice, it seems unlikely that the increase in antioxidants in melatonin-treated traumatized mice simply reflects its accumulation at the site of injury. Furthermore, oxidation potentials of melatonin and its main metabolite, N 1 -acetyl-N 2 -formyl-5-methoxykynuramine (AFMK), are ~700, and 456 and 668 mV, respectively (38) . Yet, melatonin increased levels of antioxidants with oxidation potentials of ~765 and 1145 mV. Moreover, this effect lasted for 4 days, which is much longer than the half-life of melatonin and was completely abolished by a higher dose. To exclude the possibility that the measured LMWA reflect smaller tissue damage rather than a direct effect of melatonin, LMWA at 4 days after CHI were also assessed after treatment with 2-AG. This endocannabinoid was earlier shown in our laboratory to reduce brain edema, improve motor function, reduce infarct volume, and reduce hippocampal cell death in the same model (39) . We found that only melatonin but not 2-AG treatment resulted in an increase of post-CHI brain LMWA, confirming the specificity of the melatonin-induced effect. Numerous studies support the concept that LMWA are major components of brain defense mechanisms in brain trauma. Heat-acclimated rats exhibited an increase in LMWA and milder brain edema and BBB disruption after CHI (46) . In contrast, diabetic rats (13) and apolipoprotein E-deficient mice (14) were unable to augment LMWA after CHI and showed a poor outcome. The bi-phasic response to melatonin is typical to antioxidants, which at higher doses may, via interaction with other oxidants or antioxidants, turn into pro-oxidants (12, 47) . Indeed, short incubation of HepG2 liver cells with a low concentration of melatonin induced an antioxidant effect and improved cell viability, whereas higher concentrations led to GSH depletion, and decreased cell viability (48) . In addition, coincubation of brain slices with Aβ (44) and low-dose melatonin lowered chromatin condensation and decreased the formation of iron, heme-oxygenase-1, and 8-hydroxyguanosine, whereas the opposite effects were observed with high-dose melatonin.
Several mechanisms could account for melatonin-induced potentiation of brain antioxidants after CHI. In the early postinjury phase, melatonin could have directly neutralized excess ROS, thereby leading to attenuated consumption of other endogenous antioxidants. In support of this view, 24 h after CHI, the increase in antioxidants was more prominent at the contralateral cortex, where less LMWA were presumably consumed. Gilad et al. (49) showed that treatment of macrophages with melatonin partially reversed peroxynitrite-induced suppression of mitochondrial respiration and reduced DNA damage. Neutralization of such toxic molecules may be particularly important in brain trauma. Generation of potent antioxidant metabolites of melatonin, such as AFMK, during its own oxidation, could also account for the antioxidant effect of melatonin. Alternatively, under prolonged oxidative stress, melatonin may potentiate tissue antioxidants via distinct, time-dependent mechanisms, such as induction of antioxidant enzymes and/or inhibition of pro-oxidant enzymes. Such effects of melatonin were previously demonstrated under normal and pro-oxidative conditions (50) (51) (52) (53) (54) and are implied by our findings that 4 days after CHI, overall antioxidants and in particular, ascorbic acid, were elevated in the ipsilateral cortex of melatonin-treated mice. Ascorbic acid is a powerful hydrophilic radical scavenger in biological fluids and tissues (55) , and its temporal decrease after trauma inversely correlates with brain damage and outcome (13, 56) . After reactive gliosis, astrocytes contribute to ascorbic acid homeostasis, via expression of antioxidant enzymes, synthesis of glutathione, and recycling of ascorbate. In the latter process, oxidized ascorbate is taken up by astrocytes, where it is reduced by glutathione, and then released to the extracellular fluid, where it may contribute to antioxidant defense of neurons (57) . Melatonin was shown to maintain cellular glutathione homeostasis in astrocytes (51) and neurons (52, 58) under various acute oxidative stimuli. Although such a mechanism could explain our findings, the exact mechanism by which melatonin increased brain ascorbic acid remains elusive.
Overproduction of ROS occurs within minutes after brain injury and mediates both necrotic and apoptotic cell death (3, 59) . In addition, H 2 O 2 leads to the activation of protein tyrosine-kinases followed by the stimulation of downstream signaling pathways including mitogen-activated protein kinases and phospholipase C. Such reactions, in concert, result in the activation of redoxsensitive transcription-factors, including NF-κB and AP-1 (18-19, 60) . On the other hand, in vitro oxidation of essential cysteine residues in NF-κB and AP-1 results in their inactivation, implying that cellular signaling pathways are subjected to dual redox regulation (60) . Despite the apparent link between NF-κB and apoptosis, evidence for both its anti-and pro-apoptotic effects has caused considerable controversy (18) . Hence, we assessed whether alteration of NF-κB or AP-1 could contribute to melatonin-induced neuroprotection against CHI. In agreement with previous reports (20, 21) , the present study demonstrates a transient activation of AP-1 and a longer activation of NF-κB after CHI. Interestingly, administration of melatonin 1 h after CHI inhibited the late-phase (8 days) activation of NF-κB, presumably via its prolonged antioxidant effect at the site of injury. Inhibition of NF-κB by melatonin was concomitant with improved clinical outcome, suggesting that prolonged activation of NF-κB after CHI is deleterious. This view is supported by previous reports that free radical scavengers (61) and overexpression of CuZn-superoxide-dismutase (62) inhibit NF-κB activation and reduce neuronal damage in models of cerebral ischemia. Likewise, cell lines that overexpress catalase failed to increase NF-κB activation upon H 2 O 2 treatment (63) , and N-acetylcysteine, an antioxidant that increases intracellular levels of glutathione, suppressed TNF-induced NF-κB and IKK activation and prevented phosphorylation and degradation of IκB (64) .
Interestingly, activation of NF-κB in response to CHI was not accompanied in the present study by concomitant changes in the cytosolic levels of IκBα. In most cases, degradation of IκBα proceeds and governs the nuclear translocation of NF-κB subunits (16, 60) . However, the expression of IκBα by itself is under the transcriptional control of NF-κB (65). Because we measured IκBα when NF-κB activation was already markedly increased, our results may reflect a positive feedback control of its expression by NF-κB. Alternatively, NF-κB activation under our experimental conditions may have involved activation of the phosphatidylinositol 3-kinase pathway, which does not involve proteolytic degradation of IκBα. (66) . NF-κB regulates the expression of numerous genes encoding acute-phase proteins, cell adhesion molecules, cell surface receptors, cytokines, and antioxidant enzymes (65) . Proinflammatory cytokines play crucial role in brain trauma (8) (9) and can act synergistically with ROS to induce cellular damage (67) . We have demonstrated earlier that an antioxidant (tempol) can effectively limit the action of TNFα (68) . Thus, therapeutic strategy, such as the use of melatonin, to block persistent activation of NF-κB, may either stimulate multiple downstream beneficial mechanisms and/or inhibit destructive responses such as inflammation. This would switch signaling from cell death to cell survival. In support of this notion, melatonin was shown to inhibit both lipopolysaccarideand TNF-induced activation of NF-κB (54, 69) and to prevent the subsequent activation of iNOS promotor.
AP-1, a dimer of Fos and Jun proteins, appears in a variety of combinations, such that different complexes can stimulate or inhibit the expression of different target genes (19) . Activation of AP-1 was reported after transient global forebrain ischemia (70) or after activation of NMDA receptors (71) . Yet, the pathophysiological role of AP-1 is not well defined, and oxidants were shown to exert dual effects on its activation (17, 19, 72) . Our results point that attenuation of AP-1 activation in the context of brain trauma is associated with a more favorable outcome.
Failure of melatonin to block the early activation of both transcription factors may imply that distinct mechanisms are involved in their activation at different postinjury phases. In addition, variable duration of their activation after neuronal injury may regulate different and perhaps opposing downstream cellular responses (e.g., cell survival or death).
Oxidative stress is the result of imbalance between ROS production and elimination and could be viewed as a threshold phenomenon that occurs after endogenous antioxidant mechanisms are overwhelmed. Our results demonstrate that indeed, melatonin induces neuroprotection, but its antioxidant properties are not reflected only as radical neutralizing agent. Rather, we suggest that neuroprotection is mediated via potentiation of other brain antioxidants (e.g., ascorbic acid, and other, yet unidentified compounds), thus altering the redox state of the cell and consequently attenuating NF-κB and AP-1 activation. The scheme shown in Fig. 5 summarizes our findings and proposes a mechanism by which melatonin-induced neuroprotection is mediated. Considering its endogenous nature and relative safety (73) , implementation of melatonin as a novel therapeutic modality for head trauma patients should be seriously considered. For each failed task, the mouse receives 1 point. Maximum = 10 (failure in all tasks); minimum = 0 (success in all tasks). randomly assigned for groups receiving vehicle (V) or 1, 5, or 10 mg/kg melatonin (M1, M5, and M10, respectively) and were reevaluated 24 h later. Data are means ± SE. Because only 5 mg/kg melatonin significantly lowered NSS, this dose was used for longer evaluation. *P < 0.05. B) Rate of recovery, expressed as ∆NSS (see text), was followed throughout a period of 1 wk after CHI. In comparison with vehicle (V) group (empty symbols), the 5 mg/kg melatonin (M5)-treated group (filled symbols) displayed higher ∆NSS at all time points during this period. *P < 0.05; **P < 0.01. , decreasing to basal levels thereafter (C). In contrast, 24 h after CHI, 5 mg/kg melatonin induced a significant increase in Ia at both Ep (A and B), and this effect lasted at least up to 4 days (C and D) thereafter. Melatonin was ineffective at 1 mg/kg, and at 10 mg/kg it decreased brain antioxidants (A and B). The neuroprotective endocannabinoid 2-AG did not affect late (4 days) post-CHI profile of brain antioxidants (C and D). * P < 0.05; **P < 0.01; ***P < 0.001. 3 . Effect of melatonin on post-CHI nuclear translocation of NF-κB. A) NF-κB DNA binding was determined in brain nuclear extracts, using EMSA (insert). Each experiment was repeated 3 times, and relative optical densities (CHI/Sham) were obtained using Bio-Rad Multi-Analyst. Quantitative data are means ± SE. CHI induced a robust nuclear translocation of NF-κB that was significantly inhibited by melatonin at the later (8 days) but not the earlier (24 h) posttraumatic phase. V: vehicle; M5: 5 mg/kg melatonin; C: competition with access of unlabeled NF-κB oligonucleotide; S: sham; p65: supershift assay with (+) or without (-) preincubation with anti-p65 antibody. *P < 0.05; **P < 0.01. B) Cytosolic ΙκΒα was determined by Western blot using monoclonal anti−ΙκΒα (insert). Quantitative data, expressed as relative optical densities, are means ± SE of all experiments. Neither CHI nor melatonin treatment affected ΙκΒα levels at the time points studied. their proposed modification by exogenous melatonin. CHI activates NF-κΒ via several signaling pathways. These include activation of NMDA receptors and a downstream Ras-GTP, PKB/Akt pathway, TNF release, which activates TNF receptors, and production of ROS, which impair the cellular redox-state. Melatonin may act as a direct radical scavenger, thus reducing ROS levels at early time points (hours) or can indirectly modify endogenous anti-and/or pro-oxidant enzymes, resulting in elevated levels of low molecular weight antioxidants (LMWA) at later postinjury phases (days). Lower oxidative burden on the cell leads to lower degree of activation of the transcription factors AP-1 and NF-kB. The delicate balance between death and survival signals, which is maintained under normal conditions, is switched in favor of death signals after trauma and is now turned in favor of survival signals after treatment with melatonin. This is observed, in vivo, in a better long-lasting outcome. Events that are related to melatonin are marked as dotted lines and half-filled arrows. Width of arrows is magnitude of response. Empty arrows are pathways that were not investigated in the present study.
